JP5409628B2 - 抗ｔｗｅａｋ受容体抗体の治療上の使用 - Google Patents

抗ｔｗｅａｋ受容体抗体の治療上の使用 Download PDF

Info

Publication number
JP5409628B2
JP5409628B2 JP2010519276A JP2010519276A JP5409628B2 JP 5409628 B2 JP5409628 B2 JP 5409628B2 JP 2010519276 A JP2010519276 A JP 2010519276A JP 2010519276 A JP2010519276 A JP 2010519276A JP 5409628 B2 JP5409628 B2 JP 5409628B2
Authority
JP
Japan
Prior art keywords
antibody
tweakr
seq
xaa
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010519276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535713A (ja
JP2010535713A5 (https=
Inventor
パトリシア カルプ，
Original Assignee
アッヴィ・バイオセラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・バイオセラピューティクス・インコーポレイテッド filed Critical アッヴィ・バイオセラピューティクス・インコーポレイテッド
Publication of JP2010535713A publication Critical patent/JP2010535713A/ja
Publication of JP2010535713A5 publication Critical patent/JP2010535713A5/ja
Application granted granted Critical
Publication of JP5409628B2 publication Critical patent/JP5409628B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010519276A 2007-08-03 2008-08-04 抗ｔｗｅａｋ受容体抗体の治療上の使用 Expired - Fee Related JP5409628B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95374507P 2007-08-03 2007-08-03
US60/953,745 2007-08-03
US12362308P 2008-04-09 2008-04-09
US61/123,623 2008-04-09
PCT/US2008/072146 WO2009020933A2 (en) 2007-08-03 2008-08-04 Therapeutic use of anti-tweak receptor antibodies

Publications (3)

Publication Number Publication Date
JP2010535713A JP2010535713A (ja) 2010-11-25
JP2010535713A5 JP2010535713A5 (https=) 2011-09-22
JP5409628B2 true JP5409628B2 (ja) 2014-02-05

Family

ID=40193427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010519276A Expired - Fee Related JP5409628B2 (ja) 2007-08-03 2008-08-04 抗ｔｗｅａｋ受容体抗体の治療上の使用

Country Status (12)

Country Link
US (1) US9056908B2 (https=)
EP (2) EP2545938A1 (https=)
JP (1) JP5409628B2 (https=)
KR (1) KR20100053607A (https=)
CN (1) CN102006886A (https=)
BR (1) BRPI0814768A2 (https=)
CA (1) CA2694751C (https=)
ES (1) ES2411907T3 (https=)
IL (1) IL203038A (https=)
MX (1) MX2010001378A (https=)
NZ (1) NZ582815A (https=)
WO (1) WO2009020933A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
MX2010012324A (es) * 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
ES2363669B1 (es) * 2009-06-10 2012-08-09 Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
AU2014203658B2 (en) * 2011-08-23 2016-04-28 La Trobe University FN14 binding proteins and uses thereof
HK1198832A1 (en) * 2011-08-23 2015-06-12 Transbio Ltd Fn14 binding proteins and uses thereof
WO2013166290A1 (en) * 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
NO2760138T3 (https=) 2012-10-01 2018-08-04
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
BR112015029953A2 (pt) 2013-06-14 2017-09-26 Bayer Pharma AG anticorpos anti-tweakr e seus usos
US9238034B2 (en) * 2013-07-09 2016-01-19 The Translational Genomics Research Institute FN14 antagonists and therapeutic uses thereof
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
RU2698697C2 (ru) 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
AU2015336946A1 (en) * 2014-10-23 2017-04-13 La Trobe University Fn14-binding proteins and uses thereof
CA2970565A1 (en) 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
WO2016207104A1 (de) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
EP3313523A2 (en) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
EP3313521A1 (de) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN110312534B (zh) 2016-12-21 2023-04-04 拜耳制药股份公司 具有酶促可裂解基团的抗体-药物-缀合物(adc)
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EP3814369A1 (en) 2018-06-29 2021-05-05 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Tweak-receptor agonists for use in combination with immunotherapy of a cancer
MY204672A (en) * 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2024105206A1 (en) 2022-11-17 2024-05-23 Vincerx Pharma Gmbh Antibody-drug-conjugates cleavable in a tumor microenvironment

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
US7001992B2 (en) 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
AU7549498A (en) 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
EP1080194A2 (en) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
EP2298333A3 (en) * 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
WO2001070979A2 (en) 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
JP4344519B2 (ja) 2000-12-28 2009-10-14 旭化成ファーマ株式会社 ＮＦ−κＢ活性化遺伝子
US7227007B2 (en) 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
US20040214167A9 (en) 2000-12-28 2004-10-28 Akio Matsuda NF-kappa B activating gene
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003219167A1 (en) 2002-03-19 2003-09-29 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1628679A2 (en) 2003-05-23 2006-03-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors of glial origin
DE602004006871T2 (de) 2003-07-24 2008-02-07 Amgen Inc., Thousand Oaks Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
WO2005037865A2 (en) 2003-10-16 2005-04-28 Zymogenetics, Inc. Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR
US20070298037A1 (en) 2003-10-16 2007-12-27 Fox Brian A ZTNFR14, A Tumor Necrosis Factor Receptor
US7507580B2 (en) 2003-10-16 2009-03-24 Zymogenetics, Inc. Ztnfr14, a tumor necrosis factor receptor
EP1566636A1 (en) 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
WO2005092383A1 (ja) 2004-03-26 2005-10-06 Takeda Pharmaceutical Company Limited 呼吸器疾患の予防・治療剤
EP1853312B1 (en) 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
WO2008140565A2 (en) 2006-11-08 2008-11-20 Zymogenetics, Inc. Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis
EP2240601B1 (en) 2007-12-27 2016-10-12 Compugen Ltd. Biomarkers for the prediction of renal injury
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides

Also Published As

Publication number Publication date
CA2694751A1 (en) 2009-02-12
AU2008284025A2 (en) 2010-04-01
WO2009020933A9 (en) 2009-07-09
CA2694751C (en) 2015-07-14
NZ582815A (en) 2012-07-27
AU2008284025A1 (en) 2009-02-12
WO2009020933A2 (en) 2009-02-12
JP2010535713A (ja) 2010-11-25
ES2411907T8 (es) 2013-08-30
US9056908B2 (en) 2015-06-16
MX2010001378A (es) 2010-06-02
WO2009020933A3 (en) 2009-03-26
ES2411907T3 (es) 2013-07-09
KR20100053607A (ko) 2010-05-20
EP2182982B1 (en) 2013-03-27
IL203038A (en) 2014-03-31
EP2545938A1 (en) 2013-01-16
CN102006886A (zh) 2011-04-06
EP2182982A2 (en) 2010-05-12
US20090074762A1 (en) 2009-03-19
BRPI0814768A2 (pt) 2015-03-03

Similar Documents

Publication Publication Date Title
JP5409628B2 (ja) 抗ｔｗｅａｋ受容体抗体の治療上の使用
AU2023204219B2 (en) Anti-claudin 18.2 antibodies and uses thereof
US11225519B2 (en) Treatment of cancers using anti-NKG2A agents
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
CN101238149B (zh) 新抗igf-ir抗体及其用途
CN110662552A (zh) 包含tigit结合剂的癌症治疗方法
CN109071666A (zh) 人脊髓灰质炎病毒受体（pvr）特异性抗体
KR20140113912A (ko) Her3에 특이적인 결합 분자 및 이의 용도
US20260028409A1 (en) Antibodies that bind to human ccr8
EP2185594B1 (en) Cancer treatment using humanized antibodies that bind to ephb4
KR20230019065A (ko) 항-ox40 항체 및 이의 용도
WO2024109657A1 (zh) 抗ccr8抗体及其用途
AU2008284025B2 (en) Therapeutic use of anti-tweak receptor antibodies
AU2021251989A1 (en) Anti-CD47 antibody and uses thereof
US20240174741A1 (en) Il-38-specific antibodies
HK1152670A (en) Therapeutic use of anti-tweak receptor antibodies
HK40094578A (zh) 抗密蛋白18.2抗体及其用途
WO2013177386A1 (en) Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130531

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130905

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131105

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees